Cargando…

The Impact of De‐escalation of Antianginal Medications on Health Status After Percutaneous Coronary Intervention

BACKGROUND: Antianginal medications (AAMs) can be perceived to be less important after percutaneous coronary intervention (PCI) and may be de‐escalated after revascularization. We examined the frequency of AAM de‐escalation at discharge post‐PCI and its association with follow‐up health status. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qintar, Mohammed, Towheed, Arooge, Tang, Fengming, Salisbury, Adam C., Ho, P. Michael, Grantham, J. Aaron, Spertus, John A., Arnold, Suzanne V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721850/ https://www.ncbi.nlm.nih.gov/pubmed/29054844 http://dx.doi.org/10.1161/JAHA.117.006405

Ejemplares similares

Physical Activity After Percutaneous Coronary Intervention for Chronic Total Occlusion and Its Association With Health Status
por: Peri‐Okonny, Poghni A., et al.
Publicado: (2019)

Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization
por: Zarifis, J., et al.
Publicado: (2016)

Health Status Outcomes in Older Adults Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention
por: Nguyen, Dan D., et al.
Publicado: (2023)

Beta adrenergic antagonists and antianginal drugs
por: Stever, Lindsey M., et al.
Publicado: (2021)

Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN‐CTO Registry
por: Butala, Neel M., et al.
Publicado: (2022)

Ranolazine - could an antianginal drug be used in stroke prevention?
por: Surma, Stanisław, et al.
Publicado: (2022)

Comparison of Patient-Reported vs Physician-Estimated Angina in Patients Undergoing Elective and Urgent Percutaneous Coronary Intervention
por: Saxon, John T., et al.
Publicado: (2020)

The possible antianginal effect of allopurinol in vasopressin-induced ischemic model in rats
por: Al-Zahrani, Yahya A., et al.
Publicado: (2015)

Refractory hypoxemia from intracardiac shunting following ventricular tachycardia ablation in a patient with a left ventricular assist device
por: Oates, Connor P., et al.
Publicado: (2022)

Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2023)

Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies
por: Martsevich, S.Yu., et al.
Publicado: (2021)

Association of Smoking Status With Long‐Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
por: Qintar, Mohammed, et al.
Publicado: (2019)

Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes
por: Chui, Philip W., et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Adalimumab as a potential treatment for postural orthostatic tachycardia syndrome
por: Hendrix, Andrew, et al.
Publicado: (2020)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

A Unique Case of Central Line Fracture Due to Laser Lead Extraction
por: Towheed, Arooge, et al.
Publicado: (2022)

The Antianginal Drug Perhexiline Displays Cytotoxicity against Colorectal Cancer Cells In Vitro: A Potential for Drug Repurposing
por: Dhakal, Bimala, et al.
Publicado: (2022)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review
por: Han, Ya-Ling
Publicado: (2019)

Variation in patients’ perceptions of elective percutaneous coronary intervention in stable coronary artery disease: cross sectional study
por: Kureshi, Faraz, et al.
Publicado: (2014)

The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry
por: Jang, Jae-Sik, et al.
Publicado: (2017)

Percutaneous Coronary Intervention in Patients Without Acute Myocardial Infarction in China: Results From the China PEACE Prospective Study of Percutaneous Coronary Intervention
por: Lu, Yuan, et al.
Publicado: (2018)

Percutaneous Coronary Intervention Utilization and Appropriateness across the United States
por: Thomas, Michael P., et al.
Publicado: (2015)

The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry
por: Shin, Dong-Ho, et al.
Publicado: (2019)

Erratum: Correction of Text in the Article “Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI”
por: Ki, You-Jeong, et al.
Publicado: (2022)

The Current Status of Intervention for Intermediate Coronary Stenosis in the Korean Percutaneous Coronary Intervention (K-PCI) Registry
por: Kim, Jin-Ho, et al.
Publicado: (2019)

De-Escalation of P2Y(12) Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
por: Kupka, Danny, et al.
Publicado: (2018)

Supraventricular Tachycardia and Postural Orthostatic Tachycardia Syndrome Overlap: A Retrospective Study
por: Nesheiwat, Zeid, et al.
Publicado: (2021)

De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature
por: Claassens, Daniel MF, et al.
Publicado: (2020)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Atypical Presentation of C. Difficile Infection: Report of a Case with Literature Review
por: Khan, Salman A, et al.
Publicado: (2016)

Clinical Preventability of 30‐Day Readmission After Percutaneous Coronary Intervention
por: Wasfy, Jason H., et al.
Publicado: (2014)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Zhao, Zhigang, et al.
Publicado: (2023)

Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions
por: Felix, Cordula, et al.
Publicado: (2015)

Anatomical snuff box approach for percutaneous coronary interventions – Current status
por: Deora, Surender, et al.
Publicado: (2021)

Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary Intervention
por: Hamaguchi, Toka, et al.
Publicado: (2021)

Antianginal Efficacy and Tolerability of Ranolazine as an Add-on Drug to Concomitant Medications Primarily Metoprolol in Chronic Stable Angina Patients: A Prospective, Open-Label Study
por: Khot, Anant Mahaveer, et al.
Publicado: (2017)

Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial
por: Koltowski, Lukasz, et al.
Publicado: (2019)

Percutaneous coronary intervention-associated Actinomyces oris
por: Saeed, Walaa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hq4a76fklv8h30q15gqcnneh3r